Anti-Mouse IL-4 (Clone 11B11) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse IL-4 (Clone 11B11) – Purified in vivo GOLD™ Functional Grade
Product No.: I-1071
Clone 11B11 Target IL-4 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Interleukin-4, BCGF, BCDF, B Cell Stimulating Factor, BSF-1, IaIF, HCGF, MCGF2, MFF, TCGF-2 Isotype Rat IgG1 κ Applications CyTOF® , ELISA Cap , ELISPOT , FA , ICC , IHC , in vivo , IP , N |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Immunogen Partially Purified Native Mouse IL-4 Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2830405 Applications and Recommended Usage? Quality Tested by Leinco ELISAThis antibody is useful as the capture antibody in a sandwich ELISA. The suggested coating concentration is 0.5-2.0 μg/ml. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? N IHC ICC IP CyTOF® FA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 11B11 recognizes an epitope on mouse IL-4. Background IL-4 antibody, 11B11, recognizes mouse IL-4, also known as B-cell differentiation factor (BCDF) and B-cell stimulatory factor (BSF1). IL-4 is a pleiotropic 20 kDa cytokine secreted by T helper 2 cells (Th2) cells, natural killer T (NKT) cells, mast cells, eosinophils, and basophils1,2. IL-4 signaling through the IL-4 receptor alpha chain (IL-4Ra) induces the differentiation of naive T cells to Th2 cells3,4 and stimulates B cell differentiation, proliferation, and class switching to IgG1 and IgE isotypes5. In addition, IL-4 is implicated in normal wound healing6,7 and airway inflammation in patients with asthma8. Antigen Distribution IL-4 is secreted by Th2 cells, NKT cells, mast cells, eosinophils, and basophils. Matched Pair Clone 11B11 can be used as the capture antibody in a sandwich ELISA or ELISPOT, using biotinylated clone BVD6-24G2 for detection. PubMed NCBI Gene Bank ID UniProt.org Research Area Immunology . Other Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 11B11 is a monoclonal antibody directed against mouse interleukin-4 (IL-4) and is commonly used in vivo in mice to neutralize IL-4 activity in order to study its role in immune regulation and disease models. Key in vivo applications include:
Additional common research uses of 11B11 in vivo:
Summary table of common in vivo applications of clone 11B11 in mice:
Clone 11B11 may also be used in vitro for ELISA, ELISPOT, and flow cytometry, but its distinctive value in vivo is as a functional grade antibody for blocking endogenous IL-4 activity in live mice, with validated low endotoxin formulations available for preclinical use. Commonly used antibodies or proteins paired with 11B11 (anti-mouse IL-4) in the literature include antibodies targeting other Th2 cytokines and molecules involved in related immune pathways. Specifically, these often include:
These combinations are common in several research applications:
Key related molecules also discussed in the context of IL-4/11B11 include:
Summary Table: Key Antibodies/Proteins Used with 11B11
These antibodies and proteins, when used together, enable detailed dissection of Th2 cytokine functions, immune cell polarization, and cytokine signaling networks in mouse models. Clone 11B11 is a monoclonal antibody that specifically binds to and neutralizes mouse interleukin-4 (IL-4), and has been extensively cited for its utility in immunological research, especially in dissecting Th2 responses, antibody class switching, and allergic inflammation. Key scientific findings from 11B11 citations include:
In summary, clone 11B11 is recognized as a critical reagent for unraveling the biological and pathological roles of IL-4 in mouse models, especially in studies of Th2 immunity, allergy, asthma, immunoglobulin class switching, and vaccine development. Dosing regimens of clone 11B11, an anti-mouse IL-4 monoclonal antibody, vary significantly across different mouse models depending on the disease context, experimental objectives, and target outcomes. The antibody functions as a neutralizing agent against IL-4, and its administration protocols have been optimized for specific therapeutic applications. Tumor ModelsIn cancer research, particularly in HER2-positive tumor models, 11B11 is administered at relatively high doses with frequent intervals. Studies using the D5-HER2 tumor model employed dosing every five days for a total of six doses, often in combination with trastuzumab therapy. The standard dosing recommendation for tumor models is 1 mg per mouse intraperitoneally every 4-5 days. This frequent dosing schedule appears necessary to maintain sustained IL-4 neutralization within the tumor microenvironment, where IL-4 promotes recruitment of immunosuppressive myeloid cells and alternatively activated macrophages. Infectious Disease ModelsDosing requirements differ substantially in infection models. In studies examining resistance to Listeria monocytogenes, mice received lower doses ranging from 0.01 to 0.4 mg of anti-IL-4 mAb before bacterial challenge, which successfully reduced peak bacterial burden. This suggests that prophylactic or early intervention strategies in infectious disease contexts may require less frequent dosing compared to established tumor models. Autoimmune Disease ModelsFor chronic autoimmune conditions like type 1 diabetes in NOD mice, 11B11 follows a much more spaced dosing schedule. Based on observations that the antibody does not induce the same long-term anergy as αGalCer, researchers implemented dosing every 6 weeks in NOD diabetes incidence studies. This extended interval reflects both the antibody's sustained biological activity and the chronic nature of autoimmune disease progression. Vaccine Efficacy StudiesIn vaccine research, particularly for substance use disorder vaccines, 11B11 administration protocols vary based on the immunization schedule. Studies investigating oxycodone vaccines combined the antibody with vaccine administration at multiple timepoints to modulate the immune response toward IgG2a production rather than IL-4-driven IgG1 responses. Dose Flexibility and OptimizationThe dosing of 11B11 demonstrates considerable flexibility, with adjustments made based on mouse strain, genetic background, and specific experimental endpoints. Some protocols employ an initial depletion dose of 50 μg injected intraperitoneally for iNKT cell studies, while others use repeated high-dose regimens exceeding 1 mg per injection for sustained IL-4 neutralization in tumor settings. The route of administration also matters, with intraperitoneal injection being the most common route for neutralizing antibody studies, though intravenous administration has been explored in specific contexts. References & Citations1. Yoshimoto T & Paul WE. (1994) J Exp Med. 179(4):1285–95 2. Kipnis J., at al. (2012) J Immunol. 189(9):4213-4219 3. Groth B., et al. (1992) J Exp Med. 176:1091–8 4. Murphy KM., et al. (1992) Proc Natl Acad Sci USA. 89:6065–9 5. Paul WE., et al. (1999) Annual Rev Immunol. 17:701-38 6. Maquart FX., et al. (2000) Lab Invest. 80(8):1337-43 7. Godeau, G., et al. (2000) Lab Invest. 80,1337–1343 8. Steinke JW & Borish L. (2001) Respir Res. 2(2):66-70 Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
---|---|
I-1071 | |
I-1043 | |
I-1080 | |
I-1075 | |
I-1077 | |
I-1074 | |
I-2070 |
